Compositions containing fullerenes and methods of use thereof
Novel dosing regimens for water-insoluble fullerene formulations address safety and efficacy concerns, providing effective treatment for oxidative stress and chronic inflammation by using C60 and C70 fullerenes in non-aqueous carriers, reducing toxicity and promoting cellular health.
Patent Information
- Application Number
- PCT/IB2026/054612
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
Challenges remain in the clinical development of fullerene-based compounds due to concerns over biocompatibility, solubility, and long-term toxicity, with regulatory authorities expressing caution and skepticism regarding their safety and lack of standardization in dosing.
Development of novel dosing regimens for water-insoluble fullerene formulations, such as C60 and C70 fullerenes, dissolved in non-aqueous carriers, administered at concentrations of 0.09% by weight and daily doses of 0.3 mg/kg bw, which are bioavailable and safe, reducing cell degeneration and promoting healthy cell proliferation.
The described formulations effectively treat pathological conditions associated with oxidative stress and chronic inflammation by reducing symptoms and promoting tissue repair, while being safer and more effective than previously used water-soluble fullerenes.
Smart Images

Figure IB2026054612_12112026_PF_FP_ABST
Abstract
Description
Docket No. 86592-438016COMPOSITIONS CONTAINING FULLERENES AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 803,400, filed May 9, 2025; the entire contents of this application is hereby incorporated by reference herein.TECHNICAL FIELD
[0002] This disclosure provides compositions containing fullerenes and methods of treating diseases using the same.BACKGROUND OF THE DISCLOSURE
[0003] Fullerenes are a class of carbon-based molecules composed entirely of carbon atoms arranged in closed-cage structures, such as spheres or ellipsoids. The most abundant and well-known fullerene, C60 (buckminsterfullerene) was first identified by Kroto et al. in 1985. Since their discovery, fullerenes have generated significant interest in the biomedical field due to their unique physicochemical properties, including a high number of conjugated double bonds, electron affinity, and the ability to act as radical scavengers and antioxidants (Krusic et al., 1991; Moussa et al., 1996; Dugan et al., 1997; Moussa, 2017; Kerna et al., 2020). These properties have led researchers to explore their potential in addressing oxidative stress, inflammation, and age-related pathologies.
[0004] Over the years, various fullerene derivatives (or functionalized fullerenes) — particularly water-soluble derivative forms and those functionalized for improved water-solubility — have been investigated for their therapeutic applications. Compositions comprising C60 fullerenes (functionalized forms of C60 fullerene) have been disclosed for protecting metazoans from free radical damage (TN Patent No. 0493, incorporated by reference herein) and for promoting general health and lifespan extension in mammals (US Patent Publication No. 2023 / 0060379, incorporated by reference herein). U.S. Patent No. 7,947,262 describes water-soluble fullerenes for use in treating allergic reactions and inflammatory arthritis. Water-soluble fullerenes have also been studied in neurological contexts. For instance, their neuroprotective effects have been reported in experimental models of oxidative neuronal injury (Dugan et al., 1997, 2001), Parkinson’s disease (Stetska et al., 2021), and Alzheimer’s disease (Martinez-Herrera et al., 2022; Ivkovic et al., 2024). These references focus on using water-soluble fullerenes or derivatives thereof.Docket No. 86592-438016
[0005] Numerous studies continue to evaluate the biomedical potential of fullerenes and fullerene derivatives. For example, Baati et al. (2012) demonstrated that oral administration of 4 mg / kw bw of C60 fullerene in olive oil significantly increased lifespan in rats (equivalent to 0.63 mg / kg bw of a human according to FDA: Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers). Other investigations have examined the effects of C60 fullerene derivatives on gut microbiota, glucose and lipid metabolism (Durasevic et al., 2020), 0-amyloid deposition (Armalaya et al., 2020), and pancreatic protection via modulation of inflammatory pathways (Beyaz et al., 2023). Recent literature has highlighted fullerenes' potential for topical use in wound healing (Galkina et al., 2023; Singh et al., 2024), antiviral activity against influenza (Sinegubova et al., 2023), and modulation of neuroinflammation to alleviate Parkinson’s disease symptoms via the gut-brain axis (Li et al., 2023). Several reviews have summarized these developments and explored the challenges in translating fullerene- based therapeutics to clinical use (Khudhur et al., 2024; Wilson et al., 2024; Li et al., 2025).
[0006] Despite promising findings, challenges remain in the clinical development of fullerene-based compounds. Concerns have been raised regarding the biocompatibility, solubility, and longterm toxicity of fullerene and fullerene-derivative formulations. While some fullerene preparations demonstrate biocompatibility, others have been associated with cytotoxicity, sometimes due to residual impurities (Henry et al., 2007; Kolosnjaj et al., 2007; Spohn et al., 2009; Grohn et al., 2021). Regulatory authorities have expressed caution and skepticism; for example, the Scientific Committee on Consumer Safety (SCCS, 2023) concluded that available data are insufficient to determine the safety of fullerenes and their hydroxylated forms in biomedical applications. Furthermore, Kerna et al. (2020) noted that although C60-containing products are commercially available online, there is a lack of standardization in dosing and no regulatory approval from major health authorities such as the FDA, MHRA, or EMA.
[0007] Accordingly, there remains a need for improved formulations of fullerene derivatives and techniques for treating a pathological condition associated with oxidative stress and / or inflammation, such as chronic inflammation.Docket No. 86592-438016SUMMARY OF THE DISCLOSURE
[0008] Described herein novel dosing regimens of fullerene formulations and compositions, and method of using the same to treat pathological conditions, such as pathological conditions associated with oxidative stress and / or chronic inflammation. Such fullerene formulations are bioavailable and safe. In addition, specific dosing regimens have been identified for compositions with unmodified fullerenes of high purity dissolved in a non-aqueous carrier (e.g., C60 fullerene, C70 fullerene, or a mixture of C60 and C70 fullerenes dissolved in an oil) that are significantly lower than previously described dosing regimens. This is surprising because of the observed toxicity to cells in preclinical studies and the general acceptance that water-soluble fullerenes would be active while water-insoluble fullerenes would have lower or no activity. See e.g., Wilson et al., 2024.
[0009] The treatment method not only reduces cell degeneration and death but also promotes healthy cell proliferation and tissue repair to treat the disclosed pathological conditions or decrease symptoms associated with the disclosed pathological conditions.
[0010] In one aspect, disclosed herein are methods of treating one or more pathological conditions, comprising or consisting of orally administering to a patient in need thereof a homogeneous composition, the composition comprising: a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier, wherein the C60 or C70 fullerene is present in the carrier at a concentration of 0.09 ± 0.01% by weight relative to a total weight of the homogeneous composition; and wherein the patient receives a daily oral dose of 0.3 mg of the water- insoluble C60 or C70 fullerene per kilogram of the patient's body weight (0.3 mg / kg bw / day).
[0011] In one aspect, the water-insoluble fullerene is provided in twice daily doses.
[0012] In one aspect, the composition is incorporated into a food or a nutritional composition.
[0013] In one aspect, the water-insoluble fullerene is C60 fullerene. In one aspect, the waterinsoluble fullerene is C70 fullerene. In one aspect, the water- insoluble fullerene is a mixture of C60 fullerene and C70 fullerene.
[0014] In one aspect, the homogeneous composition is incorporated into a bioequivalent composition, including mixed micelles, capable of delivering an effective dose, after daily administration by oral, percutaneous or systemic (intravenous or intramuscular) route. In oneDocket No. 86592-438016aspect, the homogeneous composition is incorporated into a biocompatible device capable of continuously delivering an effective dose of the water-insoluble fullerene.
[0015] In one aspect, the pathological condition is a neurodegenerative disease or disorder. In one aspect, the neurodegenerative disease or disorder is Alzheimer’s disease. In one aspect, the neurodegenerative disease or disorder is selected from Parkinson’s disease and parkinsonism-like diseases, ALS (amyotrophic lateral sclerosis), dementias, demyelinating diseases, Huntington’s disease, motor neuron diseases, prion diseases, neurosyphilis, and bacterial, viral, or parasitic meningitis. In one aspect, the pathological condition is selected from ulcers and soft tissue wounds, the ulcer and soft tissue wound further selected from one or more of septic origin, diabetic origin, traumatic origin, ulcerative origin, and burn origin. In one aspect, the pathological condition is osteoarthritis. In one aspect, the pathological condition is stabilizing type 2 diabetes. In one aspect, the pathological condition is stabilizing hypertension. In one aspect, the pathological condition is reducing an allergic reaction. In one aspect, the pathological condition is chronic inflammation, wherein the chronic inflammation is caused by infection, trauma, or other intrinsic causes such as autoimmune diseases. In one aspect, the bacterial meningitis or infection is caused by neurosyphilis. In one aspect, the pathological condition is neurosyphilis.BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIGs. 1A-1B is a representative image of a leg ulcer of a patient (Fig. 1A) before treatment with water-insoluble C60 and (Fig. IB) 10 days after the start of treatment.DETAILED DESCRIPTION OF THE DISCLOSURE
[0017] Described herein is the treatment or decreasing of symptoms associated with a variety of pathological conditions including neurological disorders with daily oral ingestion of unmodified C60 fullerene, fully dissolved in a suitable biocompatible solvent, in a dose of at least about 0.2 mg per kg of body weight (bw), preferably 0.3 mg / kg bw. In one aspect, the dose is less than about 1.5 mg / kg bw.I. Definitions
[0018] The following definitions supplement those in the art and are directed to the current application and are not to be imputed to any related or unrelated case, e.g. , to any commonly owned patent or application. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.Docket No. 86592-438016
[0019] The term “isolated” refers to a fullerene (e.g., a fullerene C60 or a fullerene C70) that is substantially free of other material. It is to be understood, however, that fullerenes can be formulated with diluents or adjuvants and still for practical purposes be isolated.
[0020] ‘ ‘Patient” or “subject” refers to a mammalian subject diagnosed with or suspected of having or developing a pathological condition (e.g., a disease) in connection with oxidative stress and / or chronic inflammation, such as neurodegenerative diseases or chronic inflammation diseases. Exemplary patients can be humans, apes, dogs, pigs, cattle, cats, horses, goats, sheep, rodents and other mammalians that can benefit from the therapies disclosed herein. Exemplary human patients can be male and / or female. “Patient in need thereof’ or “subject in need thereof’ means a patient diagnosed with or suspected of having a disease or disorder, for instance, but not restricted to neurodegenerative diseases or chronic inflammation diseases.
[0021] “Administering” refers to providing one or more compositions described herein to a patient or a subject. By way of example and not limitation, any of the fullerene formulations described herein can be administered orally, percutaneously and / or by injection. For example, a fullerene formulation can be administered by intravenous (i.v.) injection (such as portal vein delivery), sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, or intramuscular (i.m.) injection. One or more such routes can be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. Alternatively, or concurrently, administration can be by the oral route. Additionally, administration can also be done by surgical deposition of a bolus or pellet of cells, or positioning of a medical device.
[0022] The terms “treatment,” “treating,” and their grammatical equivalents refer to obtaining a desired pharmacologic and / or physiologic effect. In some embodiments, the effect is therapeutic, i.e., the effect partially or completely cures a disease and / or an adverse symptom attributable to the disease. In some embodiments, the term “treating” can include “preventing” a disease or a condition.
[0023] A “treatment interval” refers to a treatment cycle, for example, a course of administration of a therapeutic agent that can be repeated, e.g., on a regular schedule. In some embodiments, a dosage regimen can have one or more periods of no administration of the therapeutic agent in between treatment intervals.Docket No. 86592-438016
[0024] The terms “administered in combination,” “co-administration,” “co-administered,” “coadministering,” and “co-providing” mean that two (or more) different treatments are delivered to the subject during the course of the subject's affliction with the disorder, e.g., the two or more treatments are delivered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has ceased for other reasons. In some embodiments, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is an overlap in terms of administration. This is sometimes referred to herein as "simultaneous” or “concurrent delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective because of combined administration. For example, the second treatment is more effective, e.g., an equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, than would be seen if the second treatment were administered in the absence of the first treatment, or the analogous situation is seen with the first treatment. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that the effect of the first treatment delivered is still detectable when the second is delivered.
[0025] In some embodiments, the first treatment and second treatment can be administered simultaneously (e.g., at the same time), in the same or in separate compositions, or sequentially. Sequential administration refers to administration of one treatment before (e.g., immediately before, less than 5, 10, 15, 30, 45, 60 minutes; 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1, 2, 3, 4, 5, 6, 7, 8 or more weeks before) administration of an additional, e.g., secondary, treatment. The order of administration of the first and secondary treatment can also be reversed.
[0026] The terms “therapeutically effective amount” and “therapeutic amount,” refer to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., that amount of a fullerene formulation which is sufficient to effect treatment of neurodegenerative diseases or chronic inflammation diseases). The therapeutically effective amount can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of a composition described herein to elicit a desired response in one orDocket No. 86592-438016more subjects. The precise amount of the compositions of the present disclosure to be administered can be determined by a physician with consideration of individual differences in age, weight, extent of disease or disorder, and condition of the patient (subject).
[0027] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term “about” can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.IL Methods of Use
[0028] Described herein are methods of treating pathological conditions comprising or consisting of administering a composition comprising or consisting of a water-insoluble fullerene to a patient in need thereof. In one aspect, described herein are methods of treating pathological conditions comprising administering a composition (e.g., a homogeneous composition )
[0029] Water-insoluble fullerene compositions can be a homogenous composition. In one aspect, a water-insoluble fullerene composition comprises a water-insoluble fullerene and a carrier. For example, methods of treating pathological conditions can include administering to a patient in need thereof a homogeneous composition comprising a water-insoluble fullerene.
[0030] The water-insoluble fullerene includes a fullerene core, i.e. the fullerene skeleton without their lateral substituents, that comprise clustered carbon structures generally spherical in shape and having a carbon content of 60 carbon atoms or 70 carbon atoms. In one aspect, the water-insoluble fullerene is selected from C60 fullerene, C70 fullerene, or a mixture of C60 fullerene and C70 fullerene. In another aspect, the water-insoluble fullerene is a C60 fullerene. In another aspect, the water-insoluble fullerene is a C70 fullerene. In another aspect, the water-insoluble fullerene is a mixture of a C60 fullerene and a C70 fullerene. In another aspect, the water-insoluble fullerene is isolated. For example, the water-insoluble fullerene has a purity of greater than 99% (e.g., greater than 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, and 99.5%). In oneDocket No. 86592-438016aspect, the water-insoluble fullerene has a purity of greater than 99.9%. In another aspect, the water-insoluble fullerene consists of C60 fullerene, C70 fullerene, or a mixture of C60 fullerene and C70 fullerene. For example, the water-insoluble fullerene lacks impurities.
[0031] In another aspect, the water-insoluble fullerene is a reversible derivative of C60 fullerene, C70 fullerene, or a mixture of C60 fullerene and C70 fullerene. A reversible derivative, once administered to a patient, loses the derivative chemical structure in-vivo and returns to the original fullerene structure. By way of example, by not limitation, a fullerene can be derivatized using a cycloaddition reaction. See e.g., Moussa et al. New Journal of Chemistry 1998, 22(9): 989-992.
[0032] The water-insoluble fullerene is present in an amount ranging from about 0.01% to about 0.15% by weight relative to the total weight of the composition. For example, in one aspect, the water-insoluble fullerene is present in an amount ranging 0.07% to about 0.1% by weight (e.g., about 0.07% ± 0.01%, 0.08% ± 0.01%, 0.09% ± 0.01%, or 0.1% ± 0.01% by weight). In one embodiment, at least 0.8 mg of fullerene is dissolved per ml of the carrier, if the carrier is a liquid. As an example, it is possible to dissolve a total weight up to 0.8 mg of C60 fullerene per gram of olive or soybean oil in less than two weeks. The compositions may be pharmaceutical compositions comprising the fullerene in a therapeutically effective amount (e.g., an amount that is effective to treat a disease or a symptom of the disease).
[0033] C60 fullerene can be dissolved in a carrier, such as a pharmaceutically acceptable carrier or a biocompatible carrier. Any biocompatible carrier of natural or synthetic origin capable of completely dissolving fullerenes. In one aspect, the carrier is hydrophobic. In another aspect, the carrier is not hydrophilic. For example, in one aspect, the carrier does not comprise water. In another aspect, the carrier is not water.
[0034] A carrier can be selected from the group consisting of fats and oils. The fat or oil may be any natural or synthetic fat or oil suitable for administration to a mammal. They are not particularly restricted inasmuch as they are components which can be used in pharmaceutical preparations or in foods. Oils and fats can be hydrogenated or partially hydrogenated. They are used at a solid, a semisolid, or a liquid state. Vegetable and animal fats and oils are preferred, vegetable fats and oils are most preferred. Oils and fats include, without limitation fatty acid esters, fatty acids, fatty alcohols and fatty alcohol esters. Synthetic lipids can also be used.
[0035] Fatty acids, as defined herein, are intended to mean aliphatic monocarboxylic acids having a chain of 4 to 40 carbon atoms, which may be branched or unbranched, saturated orDocket No. 86592-438016unsaturated, cyclic or acyclic. Fatty acids may be natural or synthetic, polyunsaturated, monounsaturated or saturated. Natural fatty acids, which are usually unbranched and C4-C28 even-numbered, are preferred. Examples of fatty acids include, but are not limited to, linoleic acid, arachidonic acid, linolenic acid, gamma-linolenic acid, caprylic acid, stearic acid, myristic acid, a palmitic acid, behenic acid, undecylenic acid, oleic acid, an docosahexaenoic acid (DHA), eicosapentaenoic acid (EP A), isostearic acid, 12-hydroxy-stearic acid. Salts thereof [e.g. alkali metal salts (sodium salts, potassium salts, etc.), alkaline earth metal salts (calcium, magnesium salts etc.)] can also be employed. Fatty acid esters are preferably esters of fatty acid as defined hereinabove with C-1-C40 aliphatic or aromatic alcohols, preferably aliphatic, saturated or unsaturated, straight-chain or branched-chain, cyclic or acyclic. Alcohols can be polyols, having preferably up to five hydroxyl groups. Examples of fatty acid esters include, but are not limited to, triglycerides i.e. tri-esters of glycerol with fatty acids cited above, steroids i.e. esters of sterols with fatty acids cited above, the group consisting of the lower alkyl esters thereof (preferably methyl, propyl, butyl, isopropyl and hexyl), 1,2- or 1,3 -diglycerides, 1- or 2-monoglycerides, polyglycolysed glycerides such as sucrose fatty acid esters, polyglyceryl fatty acid esters, propylene glycol fatty acid esters. Specific examples of fatty acid esters are octyldodecyl behenate; isocetyl behenate; isocetyl lactate; isostearyl lactate; linoleyl lactate; oleyl lactate; isostearyl octanoate; isocetyl octanoate; decyl oleate; isocetyl isotearate; isocetyl laurate; isocetyl stearate; isodecyl octanoate; isodecyl oleate; isononyl isononanoate; isostearyl palmitate; myristyl isostearate; octyl isononanoate; 2-ethylhexyl isononanoate; octyl isostearate; octyldodecyl erucate; isopropyl palmitates, 2-ethylhexyl palmitate, 2-octyldecyl palmitate, branched alkyl myristates such as isopropyl myristate, t-butyl myristate, 2-octyldodecyl myristate, hexyl isostearate, butyl isostearate, isobutyl stearate, hexyl laurate, 2-hexyldecyl laurate, propylene glycol monostearate and distearate. Examples of glycerides (fatty acid esters) include, without limitation, triolein, trilinolein, tripalmitin, tristearin, trimyristin, and triarachidonin. Examples of steroids (fatty acid esters) include, without limitation, cholesteryl oleate, cholesteryl linoleate, cholesteryl myristate, cholesteryl palmitate, cholesteryl arachidate. Examples of fatty alcohols include, without limitation, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, palmityl alcohol, behenyl alcohol, hexadecyl alcohol, oleic alcohol, isostearyl alcohol, cetostearyl alcohol. They can be used as esters with C4-C40 dicarboxylic, tricarboxylic or tetracarboxylic acids.Docket No. 86592-438016
[0036] Oils may be natural oils such as vegetable oils and animal oils (composed predominantly of triglycerides), or mineral oils such as silicon oils, fluorinated oils. Liquid paraffin can also be used. Examples of natural oil include, but are not limited to, oils from plant sources, such as corn oil, wheat germ oil, soybean oil, avocado oil, rice bran oil, rapeseed oil, canola oil, sesame oil, palm (kernel) oil, olive oil, camellia oil, peanut oil, coconut oil, sunflower oil, peanut oil, orange oil, evening primrose oil, borage oil, blackcurrant seed oil, cottonseed oil, beaver oil, pineapple oil, safflower oil, copra oil, oils found in coffee, and animal oils such as turtle oil, fish oil, codliver oil.
[0037] Fats may be mineral fats or natural fats such as vegetable fats and animal fats. Petrolatum, paraffin can also be used. Examples of natural fat include, but are not limited to, butter, cocoa butter, Theobroma, peanut butter, lard, beef fat, chicken fat, horse fat, lanolin and lanolin derivatives.
[0038] Oils and fats can be polyunsaturated such as olive, corn, soybean, safflower oils, or saturated, such as palm, coconut oils and butter, or mono- unsaturated, such as olive oil and canola oil. Other suitable carriers according to the invention are diisopropyl sebacate; diisopropyl adipate; diisostearyl adipate; octyldodecyl stearoyl stearate; pentaerythrityl tetra-isononanoate; pentaerythrityl tetraisostearate; triisopropyl citrate; triisostearyl citrate; and trioctyldodecyl citrate.
[0039] As defined above, carriers can be a single carrier or a combination of two or more species. In one aspect, the carriers is butter, cocoa butter, peanut butter, olive oil, soybean oil, cod-liver oil, liquid paraffin, or a combination thereof. In another aspect, the carrier is olive oil, such as extra virgin olive oil.
[0040] In one aspect, a homogeneous composition comprises a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier, wherein the C60 or C70 fullerene is present in the carrier at a concentration of 0.09 ± 0.01% by weight relative to a total weight of the homogeneous composition.
[0041] Any of the homogeneous compositions comprising a water-insoluble fullerene described herein can be incorporated or formulated into another composition to assist in delivery to a patient in need thereof. For example, in one aspect, any of the homogeneous compositions comprising a water-insoluble fullerene described herein can be incorporated into a food, a nutritional composition, or a lipid / water emulsion. In another aspect, any of the homogeneous compositionsDocket No. 86592-438016comprising a water-insoluble fullerene described herein can be incorporated into any bioequivalent composition, including mixed micelles, capable of delivering an effective dose, after daily administration by oral, percutaneous, or systemic (intravenous or intramuscular) route. By way of example, a formulation capable of improving the intestinal absorption of fullerenes, e.g. using a lipid / water emulsions such as mixed micelles, can be developed. This may result in a reduction in the amount of the water-insoluble fullerene composition required to be effective, and therefore may reduce the required dose (e.g., the required oral dose). For example, if the intestinal absorption rate of fullerenes is increased tenfold, then the initial oral dose can be reduced by the same factor.
[0042] Intramuscular administration is also possible with an oily sterile solution. Any of the water- insoluble fullerene compositions can be formulated into an injectable lipid emulsion that can be administered by injection, for example, intravenous injection.
[0043] Administration using a continuous delivery device is also contemplated herein. For example, any of the water-insoluble fullerene compositions can be formulated to be administered with a biocompatible device capable of continuously delivering an effective dose of the waterinsoluble fullerene composition.
[0044] In some aspects, a patient in need thereof received a dose of any of the water-insoluble fullerene compositions disclosed herein. For example, in one aspect, a patient in need thereof receives a dose from about 0.05 mg / kg bw to about 0.4 mg / kg bw (e.g., from about 0.1 mg / kg bw to about 0.2 mg / kg bw, from about 0.25 mg / kg bw to about 0.35 mg / kg bw, from about 0.2 mg / kg bw to about 0.3 mg / kg bw, from about 0.3 mg / kg bw to about 0.4 mg / kg bw, about 0.1 mg / kg bw, about 0.15 mg / kg bw, about 0.2 mg / kg bw, about 0.3 mg / kg bw, about 0.4 mg / kg bw) per kilogram of the patient's body weight (bw) (mg / kg bw) of any of the water-insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives a dose of about 0.1 mg / kg bw / day of any of the water-insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives a dose of about 0.15 mg / kg bw / day of any of the water- insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives a dose of about 0.3 mg / kg bw / day of any of the water-insoluble fullerene compositions described herein. In one aspect, the dose of any of the water-insoluble fullerene compositions described herein is less than about 1.5 mg / kg bw.
[0045] In one aspect, a patient in need thereof receives a dose from about 0.05 mg / kg bw to about 0.4 mg / kg bw (e.g., from about 0.1 mg / kg bw to about 0.2 mg / kg bw, from about 0.25 mg / kgDocket No. 86592-438016bw to about 0.35 mg / kg bw, from about 0.2 mg / kg bw to about 0.3 mg / kg bw, from about 0.3 mg / kg bw to about 0.4 mg / kg bw, about 0.1 mg / kg bw, about 0.15 mg / kg bw, about 0.2 mg / kg bw, about 0.3 mg / kg bw, about 0.4 mg / kg bw) of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives a dose of about 0.1 mg / kg bw of a water-insoluble fullerene composition comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives a dose of about 0.15 mg / kg bw of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives a dose of about 0.3 mg / kg bw of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, the dose of a water-insoluble fullerene composition comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier is less than about 1.5 mg / kg bw.
[0046] In one aspect, a patient in need thereof receives an oral dose from about 0.05 mg / kg bw to about 0.4 mg / kg bw (e.g., from about 0.1 mg / kg bw to about 0.2 mg / kg bw, from about 0.25 mg / kg bw to about 0.35 mg / kg bw, from about 0.2 mg / kg bw to about 0.3 mg / kg bw, from about 0.2 mg / kg bw to about 0.4 mg / kg bw, from about 0.3 mg / kg bw to about 0.4 mg / kg bw, about 0.1 mg / kg bw, about 0.15 mg / kg bw, about 0.2 mg / kg bw, about 0.3 mg / kg bw, about 0.4 mg / kg bw) of any of the water-insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives an oral dose of about 0.1 mg / kg bw of any of the water-insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives an oral dose of about 0.15 mg / kg bw of any of the water-insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives an oral dose of about 0.3 mg / kg bw of any of the waterinsoluble fullerene compositions described herein. In one aspect, the oral dose of any of the waterinsoluble fullerene compositions described herein is less than about 1.5 mg / kg bw.
[0047] In one aspect, a patient in need thereof receives an oral dose from about 0.05 mg / kg bw to about 0.4 mg / kg bw (e.g., from about 0.1 mg / kg bw to about 0.2 mg / kg bw, from about 0.25Docket No. 86592-438016mg / kg bw to about 0.35 mg / kg bw, from about 0.2 mg / kg bw to about 0.3 mg / kg bw, from about 0.3 mg / kg bw to about 0.4 mg / kg bw, about 0.1 mg / kg bw, about 0.15 mg / kg bw, about 0.2 mg / kg bw, about 0.3 mg / kg bw, about 0.4 mg / kg bw) of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives an oral dose of about 0.1 mg / kg bw of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives an oral dose of about 0.15 mg / kg bw of a water-insoluble fullerene composition comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives an oral dose of about 0.3 mg / kg bw of a waterinsoluble fullerene composition, comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, the oral dose of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier is less than about 1.5 mg / kg bw.
[0048] In one aspect, any of the water-insoluble fullerene compositions can be provided to a patient in any appropriate treatment interval. For example, any of the water-insoluble fullerene compositions described herein can be provided to a patient, daily, multiple times a day, twice daily, weekly, twice a week, biweekly, monthly, twice a month, every other month, etc.
[0049] In one aspect, a patient in need thereof receives a daily dose from about 0.2 to about 0.4 mg (e.g., from about 0.25 mg to about 0.35 mg, from about 0.2 mg to about 0.3 mg, from about 0.3 mg to about 0.4 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg) per kilogram of the patient's body weight (bw) per day (mg / kg bw / day) of any of the water-insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives a daily dose of about 0.3 mg / kg bw / day of any of the water-insoluble fullerene compositions described herein. In one aspect, the daily dose of about 0.3 mg / kg bw / day of any of the water-insoluble fullerene compositions described herein can be split into multiple doses administered throughout the day, such as twiceDocket No. 86592-438016daily doses (e.g., two different doses of about 0.15 mg / kg bw). In one aspect, the daily dose of any of the water-insoluble fullerene compositions described herein is less than about 1.5 mg / kg bw.
[0050] In one aspect, a patient in need thereof receives a daily dose from about 0.2 mg / kg bw / day to about 0.4 mg / kg bw / day (e.g., from about 0.25 mg / kg bw / day to about 0.35 mg / kg bw / day, from about 0.2 mg / kg bw / day to about 0.3 mg / kg bw / day, from about 0.3 mg / kg bw / day to about 0.4 mg / kg bw / day, about 0.2 mg / kg bw / day, about 0.3 mg / kg bw / day, about 0.4 mg / kg bw / day) of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives a daily dose of about 0.3 mg / kg bw / day of a water-insoluble fullerene compositions, comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, the daily dose of about 0.3 mg / kg bw / day of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier can be split into multiple doses administered throughout the day, such as twice daily doses (e.g., two different doses of about 0.15 mg / kg bw). In one aspect, the daily dose of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier is less than about 1.5 mg / kg bw.
[0051] In one aspect, a patient in need thereof receives a daily oral dose from about 0.2 mg / kg bw / day to about 0.4 mg / kg bw / day (e.g., from about 0.25 mg / kg bw / day to about 0.35 mg / kg bw / day, from about 0.2 mg / kg bw / day to about 0.3 mg / kg bw / day, from about 0.3 mg / kg bw / day to about 0.4 mg / kg bw / day, about 0.2 mg / kg bw / day, about 0.3 mg / kg bw / day, about 0.4 mg / kg bw / day) of any of the water-insoluble fullerene compositions described herein. In one aspect, a patient in need thereof receives a daily oral dose of about 0.3 mg / kg bw / day of any of the waterinsoluble fullerene compositions described herein. In one aspect, the daily oral dose of about 0.3 mg / kg bw / day of any of the water-insoluble fullerene compositions described herein can be split into multiple doses administered throughout the day, such as twice daily doses (e.g., two different doses of about 0.15 mg / kg bw). In one aspect, the daily oral dose of any of the water-insoluble fullerene compositions described herein is less than about 1.5 mg / kg bw.Docket No. 86592-438016
[0052] In one aspect, a patient in need thereof receives a daily oral dose from about 0.2 mg / kg bw / day to about 0.4 mg / kg bw / day (e.g., from about 0.25 mg / kg bw / day to about 0.35 mg / kg bw / day, from about 0.2 mg / kg bw / day to about 0.3 mg / kg bw / day, from about 0.3 mg / kg bw / day to about 0.4 mg / kg bw / day, about 0.2 mg / kg bw / day, about 0.3 mg / kg bw / day, about 0.4 mg / kg bw / day) of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, a patient in need thereof receives a daily oral dose of about 0.3 mg / kg bw / day of a water- insoluble fullerene compositions comprising a waterinsoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier. In one aspect, the daily oral dose of about 0.3 mg / kg bw / day of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier can be split into multiple doses administered throughout the day, such as twice daily doses (e.g., two different doses of about 0.15 mg / kg bw). In one aspect, the daily oral dose of a water-insoluble fullerene compositions comprising a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier is less than about 1.5 mg / kg bw.
[0053] In one aspect, any of the doses described herein can be administered multiple times a day.
[0054] After administering a dose or several doses of any of the water-insoluble fullerene compositions described herein, if the patient experiences or exhibits a change in the severity of symptoms of the pathological condition for which they are treated, the dosing regimen can be altered (e.g., increased the dosing regimen if the symptom worsened, or decreased the dosing regimen if the symptom improved). For example, after multiple weeks of daily treatment (e.g., after 2 or 3 weeks of daily treatment), the water-insoluble fullerene composition can be administered at a lower dose (e.g., 50% of the first dose) or longer treatment intervals (e.g., every 24 hours rather than every 12 hours).
[0055] Any of the compositions described herein can be in any liquid pharmaceutical formulation. The carrier enables the fullerene to be formulated as tablets, pills, dragees, capsules, liposome, pomade, ointment, cream, lotion, emulsions, gels, syrups, slurries and the like. The compositions are preferably formulated for oral administration to mammals in unit dosage forms,Docket No. 86592-438016such as tablets, capsules, and oral solutions, containing suitable quantities of any of the waterinsoluble fullerene described herein. The compositions may be sterilized and / or may contain some adjuvants such as preservatives, stabilizers, acidity regulators, natural or synthetic flavor, antifoaming agents, viscosity-control agents, emulsifiers, salts for varying the osmotic pressure and / or other buffers. In addition, compositions may contain other pharmaceutically active agents.
[0056] In one aspect, a unit dosage form comprises a carrier (e.g., olive oil) and solubilized water-insoluble fullerenes. For example, in one aspect, a unit dosage form comprises from about 6 ml to about 12 ml (e.g., about 9 ml) of extra virgin olive oil and from about 0.6 mg / ml to about 1 mg / ml (e.g., about 0.8 mg / ml) of solubilized water-insoluble fullerenes (e.g., C60 fullerene, C70 fullerene, of a mixture of C60 and C70 fullerenes). In another aspect, a unit dosage form comprises from about 6 ml to about 12 ml (e.g., about 9 ml) of extra virgin olive oil and from about 0.07% by weight of the total composition to about 0.11% by weight of the total composition (e.g., about 0.09% by weight of the total composition) of solubilized water-insoluble fullerenes (e.g., C60 fullerene, C70 fullerene, of a mixture of C60 and C70 fullerenes). In one aspect, a unit dosage form comprises administering to a patient weighing, for example 60 kg, 9 ml of extra virgin olive oil containing 0.8 mg / ml of fullerenes (i.e., 0.09% by weight of the total composition), corresponding to a dose of 0.15 mg / kg of body weight.
[0057] Pathological conditions to be treated can include any disease that is related to oxidative stress and / or chronic inflammation, such as neurodegenerative diseases and chronic inflammatory diseases. Oxidative stress is an imbalance between free radicals and antioxidants. It occurs when there are too many free radicals and not enough antioxidants, leading to damage to cells, proteins, and DNA. Free radicals are important for cell functioning but cause damage in high amounts. Inflammation is a protective response involving immune cells, blood vessels, and molecular mediators. It is triggered by damage to living tissues and is a defense mechanism that evolved in higher organisms to protect them from infection and injury. The purpose of inflammation is to localize and eliminate the injurious agent and to remove damaged tissue components so that the body can begin to heal.
[0058] Exemplary neurodegenerative diseases include, but are not limited to, Alzheimer’s disease, Parkinson’s disease and parkinsonism-like diseases, ALS (amyotrophic lateral sclerosis), and Huntington’s disease.Docket No. 86592-438016
[0059] In one aspect, the pathological condition to be treated by the water-insoluble fullerene composition is dementia, such as primary dementia or secondary dementia. Exemplary dementias include, but are not limited to, Alzheimer's disease, Parkinson’s disease, parkinsonism-like diseases, and Huntington’s disease.
[0060] In one aspect, the pathological condition to be treated by the water-insoluble fullerene composition is a demyelinating disease. Exemplary demyelinating diseases include, but are not limited to, multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and progressive multifocal leukoencephalopathy (PML).
[0061] In one aspect, the pathological condition to be treated by the water-insoluble fullerene composition is a motor neuron disease. Exemplary motor neuron diseases include, but are not limited to ALS, primary lateral sclerosis, progressive bulbar palsy, progressive muscular atrophy, and spinal muscular atrophy.
[0062] In one aspect, the pathological condition to be treated is an ulcer or a soft tissue wound. An ulcer or a soft tissue wound can be of one or more of septic origin, diabetic origin, traumatic origin, ulcerative origin or burn origin. The management of these wounds is challenging as they often progress from acute to chronic inflammation due to the persistence of pathogenic microflora in the wound tissue. Chronic wounds, which include diabetic foot ulcers, venous leg ulcers and pressure ulcers, are a challenge for healthcare professionals worldwide. They are also a challenge for wound care professionals and represent a significant burden on healthcare resources worldwide (Frykberg et al., 2015)
[0063] In one aspect, the pathological condition to be treated is osteoarthritis. Osteoarthritis is a degenerative joint disease and is one of the most common types of arthritis. It is characterized by joint pain, stiffness, and swelling and primarily affects the hands, hips, back, and knees. The cartilage that cushions the ends of bones gradually wears away, leading to pain and reduced mobility. Degraded cartilage releases inflammatory mediators, leading to an increase in inflammation and more severe symptoms.
[0064] In one aspect, the pathological condition to be treated is diabetes, such as type 2 diabetes. Type 2 diabetes develops when a patient’s body becomes less sensitive to insulin. The resulting insulin resistance can also lead to inflammation, which can cause a positive feedback loop resultingDocket No. 86592-438016in greater insulin resistance. In one aspect, treating type 2 diabetes can include stabilizing blood sugar levels.
[0065] In one aspect, the pathological condition to be treated is hypertension. For example, treatment of a patient with hypertension with any of the water-insoluble fullerene compositions disclosed herein can result in stabilizing hypertension. Inflammation plays a role in the development and maintenance of hypertension.
[0066] In one aspect, the pathological condition to be treated is reducing or preventing an allergic reaction. Allergic reactions occur when the body’s immune system overreacts to harmless substances known as allergens, such as pollen, dust, certain foods, and medications. When these allergens enter the body of a sensitized individual, they provoke an immune response that includes the release of histamine and the recruitment of immune cells, which cause inflammation.
[0067] In one aspect, the pathological condition to treat is chronic inflammation. For example, chronic inflammation is caused by infection, trauma or other intrinsic causes such as autoimmune diseases. For example, in one aspect, the pathological condition to treat is neurosyphilis. Neurosyphilis is a complication of syphilis in which the Treponema pallidum bacterium that causes syphilis invades the brain and / or spinal cord of a patient. Neurosyphilis affects your central nervous system (CNS) and causes neurological symptoms. Syphilis is an STI with different signs and symptoms. Untreated neurosyphilis can result in serious medical complications, including permanent paralysis, dementia and death. There are two groups of neurosyphilis: early neurosyphilis, including asymptomatic neurosyphilis, meningeal neurosyphilis; and meningovascular neurosyphilis, and late syphilis, including general paresis and tabes dorsalis. Neurosyphilis is generally diagnoses based on symptoms, blood tests, and / or a cerebrospinal fluid (CSF) analysis.
[0068] The symptoms of neurosyphilis depend on its form. For example, asymptomatic neurosyphilis has no symptoms. Symptoms of meningeal neurosyphilis include, but are not limited to, headache, nausea, vomiting, neck stiffness, light sensitivity (photophobia), vision or hearing issues and cranial nerve dysfunction. Symptoms of meningovascular neurosyphilis include, but are not limited to, vertigo, stroke, muscle weakness, and muscle loss (atrophy). Symptoms of general paresis include, but are not limited to, mood disturbances (e.g., irritability), personality changes, changes in sleeping habits, forgetfulness, mood swings (labile mood), memory loss, impaired judgement, confusion, delusions, seizures, depression, delirium, mania, and psychosis.Docket No. 86592-438016Symptoms of tabes dorsalis include, but are not limited to, ataxia (poor muscle control), nerve pain, bladder control issues, abnormal sensation (e.g., burning or tingling, also known as paresthesia), vision changes, pupil abnormalities, ocular palsies, loss of coordination and reflexes, neuropathic arthropathy, and difficulties walking.
[0069] Severity of a symptom of any of the described pathological conditions can be monitored after administration of any of the water-insoluble fullerene compositions and a different dosage regimen (e.g., a second dosage regimen, a third dosage regimen, a fourth dosage regiment, etc.) can be determined based on the severity of the symptom. For example, if a symptom improves, a second dosage regimen can administer a smaller dose, a less frequent dose, or both a smaller and less frequent dose.
[0070] Also disclosed herein are methods of slowing disease progression and / or of slowing progression of disease symptoms in a patient in need thereof, the method comprising administering to a patient in need thereof any of the water-insoluble fullerene compositions described herein.
[0071] Also disclosed herein are methods of increasing tissue regeneration (or repair) in a patient in need thereof, the method comprising administering to a patient in need thereof any of the waterinsoluble fullerene compositions described herein.
[0072] Also disclosed herein are methods of reduce cell degeneration and / or cell death in a patient in need thereof, the method comprising administering to a patient in need thereof any of the water-insoluble fullerene compositions described herein.
[0073] Also disclosed herein are methods of reducing inflammation (e.g., localized inflammation or systemic inflammation) in a patient in need thereof, the method comprising administering to a patient in need thereof any of the water-insoluble fullerene compositions described herein.III. Methods of Making
[0074] Described herein is a method for making any of the water-insoluble fullerene compositions disclosed herein. For example, the method of making comprises the steps of: (a) charging a milling vessel with the fullerene or fullerene mixture, the carrier and balls, the milling vessel and balls being made out of any biocompatible metal or polymer; (b) agitating the mixture resulting from step (a) until a homogeneous dissolution is obtained; and (c) sterilizing the composition resulting from step (b). For example, the composition resulting from step (b) is filtered.Docket No. 86592-438016
[0075] Direct mechanical milling with the carrier can accelerate the dissolution of the fullerene or fullerene mixture. The method comprises the steps of: (a) charging a milling vessel with the fullerene, the fat or oil and balls, wherein the milling vessel and balls being made out of any biocompatible metal or polymer; (b) agitating the mixture resulting from step (a) until complete homogenization of the solution; (c) agitating the composition resulting from step (b) until complete dissolution of the fullerene; and (d) filtering the composition resulting from step (c).
[0076] In one aspect, the water-insoluble fullerene is made as described in Example 1.EXAMPLES
[0077] These Examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.
[0078] Example 1. Method of making a water-insoluble fullerene C60 composition.
[0079] The purity of C60 (purity; 99.98%) was confirmed by several analytical methods as previously described (Keykhosravy et al., 2019).
[0080] The authenticity of the extra virgin olive oil (Chemlali variety, Tunisia) used to dissolve fullerene C60 and prepare the composition was also confirmed by ultra-high performance-MS / MS (UHPLC-MS / MS) as previously described (De Person et al., 2024).
[0081] The preparation of fullerene C60-olive oil solutions was obtained by dissolving fullerene C60 in extra virgin olive oil while protecting the solution from light and then filtering through a 2 pm filter. The final concentration of fullerene C60 in the oil was determined by spectrophotometric measurement at 330 nm, after appropriate dilution of the fullerene C60-olive oil solution in toluene for spectrometry. The exact concentration was calculated by comparison with a standard solution of pure fullerene C60 dissolved in toluene using the same dilution factor. The final concentration of fullerene C60 was 0.8 mg / ml of olive oil with an accuracy of 1%. This corresponds to a final concentration of 0.89 mg of fullerene C60 per gram of olive oil or a concentration of 0.089%, relative to the total weight of the final homogeneous solution. In subsequence Examples, this formulation is referred to as a water-insoluble fullerene C60 formulation.
[0082] The oily fullerene solution can be administered either as it is or after it has been dispersed in an aqueous solution to form mixed micelles. The latter method is intended to promote better intestinal absorption.
[0083] Example 2. Treatment of a case of amyotrophic lateral sclerosis (ALS).
[0084] Mrs. XI was 76 years old when she was diagnosed with bulbar type amyotrophic lateralDocket No. 86592-438016sclerosis (ALS) after experiencing general fatigue, muscle wasting and speech problems (articulation of words). After four years of symptomatic treatment, the patient experienced increasing difficulty in swallowing and developed a severe speech disorder. At this stage, her doctor warned the family that she was at risk of dying from respiratory failure.
[0085] Mrs. XI was administered an oral bolus of 36 mg of a water- insoluble fullerene C60 formulation every two weeks for 4 years. Mrs. XI died of respiratory failure at the age of 84 after four years of treatment with Fullerene C60.
[0086] This example shows significant improvement in ALS symptoms after a patient began receiving regular treatments with a water-insoluble fullerene C60 formulation.
[0087] Example 3. Treatment of a case of Alzheimer’s disease.
[0088] Mr. Y1 was 73-year-old and suffering from Alzheimer's disease, stage 6 on the Global Disease Severity Scale (GDS or Reisberg Scale) and showed severe dementia and aggressiveness.
[0089] Mr. Y1 was administered a 30 mg oral bolus of a water-insoluble fullerene C60 formulation once a week for four weeks. The patient became calm and regained almost all of his memory, which is close to level 1 on the GDS scale.
[0090] This example shows significant improvement in Alzheimer’s disease symptoms after a patient began receiving regular treatments with a water-insoluble fullerene C60 formulation.
[0091] Example 4. Treatment of another case of Alzheimer disease.
[0092] Mr. Y2, 79 years old, has had Alzheimer's disease for 8 years. He was at stage 6 (GDS) with severe cognitive deficits, specifically dementia.
[0093] After six days of treatment with a daily oral dose of a water-insoluble fullerene C60 formulation at 0.2 mg / kg bodyweight (bw) divided into 2 doses, morning and evening, his mood improved significantly. He became lucid and calm (level 2, GDS). After 9 days of treatment, his mood improved again (level 1, GDS) and he mostly sleeps through the night without nocturnal restlessness. After 11 days of treatment, the patient became very calm, with minimal memory problems. After 20 days of treatment, the patient was calm again.
[0094] This example shows significant improvement in Alzheimer’s disease symptoms after a patient began receiving regular treatments with a water-insoluble fullerene C60 formulation.
[0095] Example 5. Treatment of a case of Parkinson’s disease.
[0096] Mr. Y3 was 70 years old when he was diagnosed with Parkinson's Disease. He is now (age 74) at stage 1.5 of the disease of the unified Parkinson disease rating scale (UPDRS).Docket No. 86592-438016
[0097] In addition to slowness of movement and difficulty walking, for several months the patient had difficulty bending down to wash his face due to lower back pain.
[0098] Mr. Y3 took C60 at a daily dose of a water-insoluble fullerene C60 formulation at 0.2 mg / kg bw, divided into 2 doses, morning and evening.
[0099] On the fifth day of treatment, the patient was surprised to be able to bend down normally, without lower back pain, to wash his face with both hands. After two weeks of treatment, this gentleman has no pain or stiffness. He has also regained an almost normal gait. Also, before the treatment, the patient could not put on his trousers without sitting on a chair. After two weeks of treatment, he was able to stand on one leg to put the other leg into his trousers and vice versa.
[0100] This example shows significant improvement in Parkinson’s disease symptoms after a patient began receiving regular treatments with a water-insoluble fullerene C60 formulation.
[0101] Example 6. Treatment of a case of Alzheimer's disease complicated by type 2 diabetes, decubitus ulcers, severe osteoporosis and a pelvic fracture.
[0102] Mrs. X2 was 71 years old and has been retired for 11 years. Her medical history is as follows:
[0103] 1. Hypertension for 42 years, very poorly controlled on triple therapy, with systolic blood pressure between 15 and 17 and diastolic blood pressure between 8.5 and 10.
[0104] 2. Type II diabetes, poorly controlled with oral antidiabetic medication and high-dose insulin therapy (80 lU / day) for 5 years. Her fasting blood glucose fluctuates between 2 and 3.5 g / dl and her hemoglobin A1C (HbAlC) was 9.6 %.
[0105] 3. She had surgery for lumbar spinal stenosis but still suffers from debilitating neuropathic pain.
[0106] 4. She has had arterial disease of the lower limbs for several months, with multiple leg ulcers (3 to 4 per leg) (Fig. 1A).
[0107] 5. Advanced osteoporosis and a pelvic fracture caused by a fall three days before starting treatment with C60. The doctor prescribed bed rest for at least three months.
[0108] 6. Alzheimer's disease for 4 years, at stage 6 (GDS), with moderate cognitive deficits, but above all with excessive irritability and akathisia.
[0109] Of note, Mrs. X2 had a circulating CRP (C-reactive protein in the blood), a classic marker of inflammation, of 20 mg / L before starting treatment whereas the normal level for adults is 6 mg / L.Docket No. 86592-438016
[0110] She began oral treatment with a water- insoluble C60 fullerene formulation at a daily dose of 0.3 mg / kg body weight divided into 2 doses, morning and evening.
[0111] The current results are as follows:
[0112] On the fifth day (D5) of treatment, her condition improved: she was lucid and calm (level 2, GDS) and suffered much less from her fracture. The doctor noted that all the ulcers had begun to heal.
[0113] On D7 of the treatment, the glycemic cycle is balanced with a maximum blood sugar of 1.76 g / 1. Blood pressure is also more stable.
[0114] On the D10 of treatment, the patient's mood has improved; in particular, she sleeps through the night without nocturnal agitation. The pressure sores are completely healed (Fig. IB).
[0115] On DI 5 of treatment, the patient is very calm (GDS level 1) and manages to get around with her walking frame despite her fracture.
[0116] On D20 from the start of treatment, the patient walks normally with her walking frame. She prepares her meals without assistance. The ulcers on her legs have also disappeared. Circulating CRP, the marker of inflammation, returned to normal and was <6 mg / L.
[0117] This example shows significant improvement in Alzheimer’s disease symptoms, type 2 diabetes symptoms, and osteoarthritis, and regulated blood pressure after a patient began receiving regular treatments with a water-insoluble fullerene C60 formulation.
[0118] Example 7. Treatment of a case of neurosyphilis.
[0119] Mr. Y4 was 66 years old when he was diagnosed with neurosyphilis, specifically late neurosyphilis. His symptoms included mood disturbances, movement issues, and nerve pain.
[0120] He began oral treatment with a water-insoluble C60 fullerene formulation at a daily dose of 0.3 mg / kg bw, divided into 2 doses per day.
[0121] His symptoms began improving 5 days after beginning treatment. After 7 days of treatment, the motor disturbances and nerve pain completely disappeared. The patient was able to sit quietly in a chair and sleep without restlessness.
[0122] This example shows significant improvement in neurosyphilis symptoms after a patient began receiving regular treatments with a water-insoluble C60 fullerene formulation.
[0123] Example 8. A pilot study for the treatment of Alzheimer's disease.
[0124] Objective
[0125] The study was designed to evaluate the efficacy and safety of the daily oral administrationDocket No. 86592-438016of an oily fullerene C60 solution (0.8 mg / ml) dissolved in extra virgin olive oil, in six patients with Alzheimer's disease.
[0126] Patients and treatment
[0127] The study included six patients who met the DSM-5 criteria for probable Alzheimer's disease. Their families requested that they participate in the study while receiving standard treatment. Informed consent was obtained from their legal guardians.
[0128] The study included four women and two men with an average age of 69 years (±5 years). Three of the women and one of the men had moderate Alzheimer's disease, with an average MiniMental State Examination (MMSE) score of 15 / 30 at baseline. The remaining patients (one woman and one man) had severe Alzheimer's disease, achieving an average MMSE score of 8 / 30.
[0129] All patients were receiving anticholinesterase therapy. The two patients with severe disease had been taking memantine at a dose of 20 mg per day for over a year.
[0130] All patients received the new treatment at a dose of 0.3 mg / kg twice daily for one week, followed by 0.15 mg / kg daily for a further fourteen days. They were followed up on days 7, 14, 21, and 30 days after treatment cessation.
[0131] Safety
[0132] No adverse effects were observed in patients during this trial. The product appears to be well tolerated, with no signs of rejection were noted.
[0133] Efficacy
[0134] Cognitively, an objective improvement was observed in patients with moderate Alzheimer's disease, with an average gain of 3 points in the MMSE score between the beginning and end of treatment (an increase in the MMSE score from 15 to 18 between day 0 and day 21). One month after the end of treatment, the average score returned to its initial value of 18 / 30.
[0135] From a behavioral perspective, all caregivers reported an improvement in mood by the fifth day of treatment.
[0136] Thanks to the GAD-7 (Generalized Anxiety Disorder 7 item) score, which was administered to caregivers at three points in time — before treatment began, when treatment ceased, and 30 days afterwards — we were able to record an average improvement from 19 to 15, representing an average gain of four points per person by the end of treatment. However, one month after treatment ceased, this gain decreased by three points, resulting in an average GAD-7 score of 18.Docket No. 86592-438016
[0137] According to their caregivers, five out of six patients experienced calmer nights and a reduction in night-time agitation. On average, the agitation returned two weeks after treatment ceased.
[0138] Inflammation: Levels of C-reactive protein (CRP) decreased by an average of two points during treatment and returned to baseline levels one month after treatment ceased.
[0139] Hypertension: Three patients had both hypertension and diabetes. We observed an average improvement of two mmHg in systolic blood pressure (decreasing from 15 to 13 mmHg) and one mmHg in diastolic blood pressure (decreasing from nine to eight mmHg).
[0140] Blood glucose: Glycemic cycle values became much more stable during treatment, beginning on day seven, with an average improvement of 0.5 g / L in fasting blood glucose. HbAlc decreased by an average of 1.3 % in a test performed one month after treatment was discontinued.
[0141] Arteriopathy: two patients presented with stage 3-4 lower limb arteriopathy and multiple, debilitating leg ulcers (three in both cases), which had been present for five years. We observed marked improvement in their condition during treatment, followed by complete regression two months after discontinuing treatment.
[0142] Pelvic fracture: One of our patients suffered a pelvic fracture three days before starting treatment. Her doctor prescribed three months of bed rest. By the fifteenth day, her pain had reduced by two points on the numerical rating scale and she was able to walk with a walker despite the fracture. By the twentieth day, she was walking normally.
[0143] Discussion
[0144] These results are unequivocal. The oily fullerene solution has a rapid effect on patients' moods and behavior. Based on the effects of this fullerene solution on diabetic wounds, it appears that this product can halt neurodegeneration and stimulate tissue repair.
[0145] The fact that the effects subside a few days after treatment is stopped clearly indicates that the product is gradually being eliminated from the body. This finding is consistent with previous pharmacokinetic results obtained in rats. However, the fact that the effects subside after treatment is stopped also suggests that the disease has not been completely cured. It should be noted that this treatment was only prescribed for three weeks, with the dose being halved from the end of the first week. It should be noted that resuming the initial treatment allows the symptoms to be cured again.Docket No. 86592-438016
[0146] Individual resultsTable 1.Ms XI, Day 0 (DO, Day 7 (After Day 21 (After Day 51 (30 69 years before fullerene fullerene fullerene days after Treatment : administration administration) administration) stopping the Donepezil (10 treatment) mg / day)DSM-5 Alzheimer’s disease (moderate)MMS 18 19 22 19GAD-7 18 18 14 17Sleep 6 nights / 7 6 nights / 7 7 nights / 7 6 nights / 7 disturbed disturbed calm disturbed BP 16 / 9 15 / 9 13 / 8 13 / 7Fasting blood 2.7 g / 1 2.1 g / 1 2.1 g / 1 2.3 g / 1 glucoseHbAlC 8.7 % 7.0 %Arteriopathy 3 infected 3 infected 3 small, Disappearance ulcerations ulcerations but uninfected of scabs small in size scabsOthers CRP : 10 mg / 1 CRP : 9 mg / 1 CRP : 8 mg / 1 CRP : 6 mg / 1Table 2.Ms X2, Day 0 Day 7 Day 21 Day 51 (30 72 years days after Treatment : stopping the Donepezil (10 treatment) mg / day)DSM-5 Alzheimer’s disease (moderate)MMS 15 15 18 16GAD-7 17 17 13 18Docket No. 86592-438016Sleep 6 nights / 7 7 nights / 7 7 nights / 7 7 nights / 7 Disturbed Disturbed (5 / 7) calm Disturbed (4 / 7) BP 14 / 9 14 / 9 13 / 7 14 / 7Fasting blood 1.9 g / 1 1.7 g / 1 1.5 g / 1 1.7 g / 1 glucoseHbAlC 11.8 % 8.5 %Arteriopathy 2 infected 2 infected 2 small, Disappearance ulcerations ulcerations but uninfected of scabs small in size scabsOthers CRP : 9 mg / 1 CRP : 8 mg / 1 CRP : 8 mg / 1 CRP : 6 mg / 1Table 3.Ms X3, Day 0 Day 7 Day 21 Day 51 (30 62 years days after Treatment : stopping the Donepezil (10 treatment) mg / day)DSM-5 Alzheimer’s disease (moderate)MMS 14 14 16 13GAD-7 19 19 15 18Sleep 4 nights / 7 5 nights / 7 5 nights / 7 4 nights / 7 disturbed disturbed calm disturbed BP 15 / 10 14 / 9 13 / 8.5 14 / 8Fasting blood 1.8 g / 1 1.7 g / 1 1.3 g / 1 1.6 g / 1 glucoseHbAlC 8.7 % 7.0 %Arteriopathy 0 0 0 0Others CRP : 8 mg / 1 CRP : 8 mg / 1 CRP : 6 mg / 1 CRP : 6 mg / 1Docket No. 86592-438016Table 4.Mr Yl, Day 0 Day 7 Day 21 Day 51 (30 62 years days after Standard stopping the Treatment : treatment) Donepezil (10mg / day)DSM-5 Alzheimer’s disease (moderate)MMS 13 14 16 12GAD-7 19 19 16 21Sleep 2 nights / 7 3 nights / 7 3 nights / 7 2 nights / 7 disturbed disturbed calm disturbed BP 12 / 6 11 / 6 12 / 7 12 / 6Fasting blood 1.3 g / 1 1.3 g / 1 1.3 g / 1 1.3 g / 1 glucoseHbAlC - -Arteriopathy 0 0 0 0Others CRP : 8 mg / 1 - CRP : 6 mg / 1 CRP : 8 mg / 1Table 5.Mr Y2, Day 0 Day 7 Day 21 Day 51 (30 60 years days after Treatment : stopping the Donepezil (10 treatment) mg / day) andmemantine (20mg / day)DSM-5 Alzheimer’s disease (severe)MMS 8 8 9 8Docket No. 86592-438016GAD-7 21 19 18 19Sleep 3 nights / 15 4 nights / 15 5 nights / 15 5 nights / 7 disturbed disturbed disturbed disturbed BP 12 / 7 12 / 8 13 / 7 12 .5 / 8Fasting blood 1.3 g / 1 1.1 g / 1 1.1 g / 1 1.2 g / 1 glucoseHbAlC - -Arteriopathy 0 0 0 0Others - - - -Table 6.Ms X4, Day 0 Day 7 Day 21 Day 51 (30 63 years days after Treatment : stopping the Donepezil (10 treatment) mg / day) andmemantine (20mg / day)DSM-5 Alzheimer’s disease (severe)MMS 8 8 9 9GAD-7 21 21 18 19 Sleep 1 nights / 15 2 nights / 15 2 nights / 15 2 nights / 7 disturbed disturbed disturbed disturbed BP 12 / 8 12 / 7 13 / 8 12 .5 / 7Fasting blood 1.2 g / 1 1.3 g / 1 1.3 g / 1 1.3 g / 1 glucoseHbAlC - -Docket No. 86592-438016Arteriopathy 0 0 0 0Others - - - -
[0147] Statements
[0148] Statement 1. A method of treating one or more pathological conditions, comprising orally administering to a patient in need thereof a homogeneous composition, the composition comprising: a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier, wherein the C60 or C70 fullerene is present in the carrier at a concentration of 0.09 ± 0.01% by weight relative to a total weight of the homogeneous composition; and wherein the patient receives a daily oral dose of 0.3 mg of the water-insoluble C60 or C70 fullerene per kilogram of the patient's body weight (0.3 mg / kg bw / day).
[0149] Statement 2. The method of statement 1 , wherein the water-insoluble fullerene is provided in twice daily doses.
[0150] Statement 3. The method of any one of statements 1 and 2, wherein the composition is incorporated into a food or a nutritional composition.
[0151] Statement 4. The method of any one of statements 1-3, wherein the water-insoluble fullerene is C60 fullerene.
[0152] Statement s. The method of any one of statements 1-3, wherein the water-insoluble fullerene is C70 fullerene.
[0153] Statement 6. The method of any one of statements 1-3, wherein the water-insoluble fullerene is a mixture of C60 fullerene and C70 fullerene.
[0154] Statement 7. The method of any one of statements 1 -6 wherein the homogeneous composition is incorporated into a bioequivalent composition, including mixed micelles, capable of delivering an effective dose, after daily administration by oral, percutaneous, or systemic (intravenous or intramuscular) route.
[0155] Statement 8. The method of any one of statements 1-7 wherein the homogeneous composition is incorporated into a biocompatible device capable of continuously delivering an effective dose of the water-insoluble fullerene.
[0156] Statement 9. The method of any one of statements 1-8, wherein the pathologicalDocket No. 86592-438016condition is a neurodegenerative disease or disorder.
[0157] Statement 10. The method of statement 9, wherein the neurodegenerative disease or disorder is Alzheimer’s disease.
[0158] Statement 11. The method of statement 9, wherein the neurodegenerative disease or disorder is selected from Parkinson’s disease and parkinsonism-like diseases, ALS (amyotrophic lateral sclerosis), dementias, demyelinating diseases, Huntington’s disease, motor neuron diseases, prion diseases, neurosyphilis, and bacterial, viral, or parasitic meningitis.
[0159] Statement 12. The method of any one of statements 1-8, wherein the pathological condition is selected from ulcers and soft tissue wounds, the ulcer and soft tissue wound further selected from one or more of septic origin, diabetic origin, traumatic origin, ulcerative origin, and burn origin.
[0160] Statement 13. The method of any one of statements 1-8, wherein the pathological condition is osteoarthritis.
[0161] Statement 14. The method of any one of statements 1-8, wherein the pathological condition is stabilizing type 2 diabetes.
[0162] Statement 15. The method of any one of statements 1-8, wherein the pathological condition is stabilizing hypertension.
[0163] Statement 16. The method of any one of statements 1-8, wherein the pathological condition is reducing an allergic reaction.
[0164] Statement 17. The method of any one of statements 1-8, wherein the pathological condition is chronic inflammation, wherein the chronic inflammation is caused by infection, trauma, or other intrinsic causes such as autoimmune diseases.
[0165] Statement 18. The method of statement 11 or statement 17, wherein the bacterial meningitis or infection is caused by neurosyphilis.
Claims
Docket No. 86592-438016What is claimed is:
1. A method of treating one or more pathological conditions, comprising orally administering to a patient in need thereof a homogeneous composition, the composition comprising:a water-insoluble fullerene selected from C60 fullerene, C70 fullerene, or mixture of C60 fullerene and C70 fullerene dissolved in a biocompatible carrier, wherein the C60 or C70 fullerene is present in the carrier at a concentration of 0.09 ± 0.01% by weight relative to a total weight of the homogeneous composition; and wherein the patient receives a daily oral dose of 0.3 mg of the water-insoluble C60 or C70 fullerene per kilogram of the patient's body weight (0.3 mg / kg bw / day).
2. The method of claim 1, wherein the water-insoluble fullerene is provided in twice daily doses.
3. The method of claim 1, wherein the composition is incorporated into a food or a nutritional composition.
4. The method of claim 1 , wherein the water-insoluble fullerene is C60 fullerene.
5. The method of claim 1, wherein the water-insoluble fullerene is C70 fullerene.
6. The method of claim 1 , wherein the water-insoluble fullerene is a mixture of C60 fullerene and C70 fullerene.
7. The method of claim 1, wherein the homogeneous composition is incorporated into a bioequivalent composition, including mixed micelles, capable of delivering an effective dose, after daily administration by oral, percutaneous, or systemic (intravenous or intramuscular) route.
8. The method of claim 1, wherein the homogeneous composition is incorporated into a biocompatible device capable of continuously delivering an effective dose of the water-insoluble fullerene.
9. The method of claim 1, wherein the pathological condition is a neurodegenerative disease or disorder.Docket No. 86592-43801610. The method of claim 9, wherein the neurodegenerative disease or disorder is Alzheimer’s disease.
11. The method of claim 9, wherein the neurodegenerative disease or disorder is selected from Parkinson’s disease and parkinsonism-like diseases, ALS (amyotrophic lateral sclerosis), dementias, demyelinating diseases, Huntington’s disease, motor neuron diseases, prion diseases, neurosyphilis, and bacterial, viral, or parasitic meningitis.
12. The method of claim 1, wherein the pathological condition is selected from ulcers and soft tissue wounds, the ulcer and soft tissue wound further selected from one or more of septic origin, diabetic origin, traumatic origin, ulcerative origin, and burn origin.
13. The method of claim 1, wherein the pathological condition is osteoarthritis.
14. The method of claim 1, wherein the pathological condition is stabilizing type 2 diabetes.
15. The method of claim 1, wherein the pathological condition is stabilizing hypertension.
16. The method of claim 1, wherein the pathological condition is reducing an allergic reaction.
17. The method of claim 1 , wherein the pathological condition is chronic inflammation, wherein the chronic inflammation is caused by infection, trauma, or other intrinsic causes such as autoimmune diseases.
18. The method of claim 11, wherein the bacterial meningitis or infection is caused by neurosyphilis.
19. The method of claim 17, wherein the bacterial meningitis or infection is caused by neurosyphilis.
